RT Book, Section A1 Lichtman, Marshall A. A1 Kaushansky, Kenneth A1 Prchal, Josef T. A1 Levi, Marcel M. A1 Burns, Linda J. A1 Linch, David C. SR Print(0) ID 1189334707 T1 The Chronic Myelogenous Leukemias T2 Williams Manual of Hematology, 10e YR 2022 FD 2022 PB McGraw-Hill Education PP New York, NY SN 9781264269204 LK hemonc.mhmedical.com/content.aspx?aid=1189334707 RD 2024/03/28 AB BCR-ABL1–positive chronic myelogenous leukemia (CML) results from a somatic mutation in a pluripotential lymphohematopoietic cell, yielding a fusion oncogene (BCR-ABL1).CML is characterized by granulocytic leukocytosis, granulocytic immaturity, basophilia, anemia, and often thrombocytosis in the blood, intense leukemic granulocytic precursor expansion in the marrow, and splenomegaly.The natural history of the disease is to evolve into an accelerated phase in which cytopenias develop and response to chronic phase therapy is lost; either the chronic or accelerated phase can undergo further clonal evolution to acute leukemia.This natural history has been modified significantly by the introduction of inhibitors of the constitutive kinase activity of the BCR-ABL1 oncoprotein.